Publications by authors named "Dora Kocsis"
Article Synopsis
- Opioid antagonists like naloxone and naltrexone are commonly used in medicine and can cross the blood-brain barrier; modifying their structure (like with methylnaltrexone) reduces this ability.
- The study introduces naltrexone-14-O-sulfate, a zwitterionic compound, and assesses its pharmacological properties, finding it has better selectivity for opioid receptors compared to naltrexone and naloxone, even though it has a lower binding affinity.
- Naltrexone-14-O-sulfate was shown to effectively counteract morphine's effects in mouse models, suggesting unexpected central nervous system (CNS) penetration, prompting the need for further research on its
What Is Known: There is a growing number of evidence showing, that the cannabinoid receptor 1 (CB1) antagonist rimonabant has many non-cannabimimetic actions, such as affecting the opioid system. The direct effect of rimonabant on opioid receptors has been studied so far mainly on μ-opioid receptors. However recently the δ-opioid receptor (DOR) receives much more attention as before, due to its potential therapeutic applications, such as nociception or treatment for psychiatric disorders.
View Article and Find Full Text PDF